Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03043664
Recruitment Status : Recruiting
First Posted : February 6, 2017
Last Update Posted : July 4, 2019
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Ipsen
Information provided by (Responsible Party):
Duke University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 1, 2020
  Estimated Study Completion Date : June 1, 2020